1.Controversies in the treatments of prostate cancer.
Chinese Medical Journal 2013;126(15):2972-2977
Humans
;
Male
;
Prostatic Neoplasms
;
therapy
2.Urologic Applications of Cryo-Immunology.
Abhinav SIDANA ; Ronald RODRIGUEZ
Korean Journal of Urology 2009;50(7):629-634
PURPOSE: Cryoablation is gaining acceptance as a primary treatment of localized metastatic urologic malignancies as well as a salvage therapy. Anecdotal clinical reports suggest that cryoablation can induce a systemic antitumor immune response, which has been confirmed in animal models also. MATERIALS AND METHODS: A review of the relevant literature was performed to suggest urologic applications of cryo-immunology. RESULTS: This article reviews the existing evidence regarding cryo-immunology and discusses the mechanisms for generation of an anti-tumor immune response. CONCLUSIONS: Our findings suggest combining cryoablation with other immunotherapeutic approaches to devise a cryo-immunotherapeutic strategy with potential to impact the progression of metastatic disease.
Cryosurgery
;
Immunotherapy
;
Kidney Neoplasms
;
Models, Animal
;
Prostatic Neoplasms
;
Salvage Therapy
3.Dramatic Decline of PSA and Symptom Improvement after Estramustine Withdrawal in a Hormone-refractory Prostate Cancer Patient.
Kyo Ik MO ; Ki Ho KIM ; Young Jin SEO ; Kyung Seop LEE
Korean Journal of Urology 2007;48(7):751-753
In some patients with prostate cancer and who manifest disease progression during maximal androgen blockade(MAB) therapy, discontinuation of antiandrogen treatment might result in a significant fall in the level of serum prostate-specific antigen(PSA), and this is often correlated with clinical improvement(antiandrogen withdrawal syndrome). However, a decline in the PSA level after the withdrawal of estramustine phosphate is extremely rare. We report here on a case of dramatic decline in the PSA level after withdrawal of estramustine phosphate in a patient with hormone refractory prostate cancer.
Disease Progression
;
Drug Therapy
;
Estramustine*
;
Humans
;
Prostate*
;
Prostatic Neoplasms*
4.Single agent chemotherapy with cyclophosphamide in patients with advanced prostatic cancer.
Korean Journal of Urology 1993;34(4):626-630
Eleven patients with advanced prostatic cancer who had received single agent chemotherapy with cyclophosphamide were evaluated. All patients had pathologically confirmed prostatic adenocarcinoma and were unresponsive to or in relapse after hormonal therapy. They were treated intravenously with 200mg/m2 cyclophosphamide daily for four days every four weeks. The National prostatic Cancer Project(NPCP) response criteria were used. so objective response included patients with complete or partial response as well as objectively stable disease as defined by NPCP response criteria. The response rate was 54.6 %. with three partial response(27.3 8 ) and three objectively stable disease(27.3) of the eleven patients. All the six patients with partial response and objectively stable disease lived longer than 4 year, whereas for the five patients with objective progression. only two patient lived longer than 1 year. Toxicity was mild and tolerable. Mild and asymptomatic cyclophosphamide-induced hyponatremia was observed in two patients and hemorrhagic cystitis of mild degree was observed in one patient Severe hematologic and gastrointestinal toxicities were not observed.
Adenocarcinoma
;
Cyclophosphamide*
;
Cystitis
;
Drug Therapy*
;
Humans
;
Hyponatremia
;
Prostatic Neoplasms*
;
Recurrence
5.Adenovirus-Mediated Toxic Gene Therapy Using Cytosine Deaminase and Osteocalcin Promoter for the Treatment of Prostate Cancer.
Hong Seok PARK ; Jae Hyun BAE ; Du Geon MOON ; Hyun Yee CHO ; Chinghai KAO ; Thomas A GARDNER ; Jun CHEON
Korean Journal of Urology 2000;41(12):1437-1444
No abstract available.
Cytosine Deaminase*
;
Cytosine*
;
Genetic Therapy*
;
Osteocalcin*
;
Prostate*
;
Prostatic Neoplasms*
6.Chemotherapy With Androgen Deprivation for Hormone-Naïve Prostate Cancer.
Byeong Jo JEON ; Bum Sik TAE ; Jae Young PARK
Korean Journal of Urological Oncology 2017;15(1):11-15
Research regarding the treatment of metastatic prostate cancer has been undergoing dramatic progress. Treatment of hormone-naïve metastatic prostate cancer includes surgical castration and medical castration that lowers androgen level in the blood using drugs. Although these androgen deprivation therapies are very effective, hormone-naïve metastatic prostate cancer finally leads to castration-resistant prostate cancer because resistance to surgical or medical castration occurs. The treatment at this stage includes not only docetaxel, but also new androgen synthesis inhibitor or androgen receptor inhibitors such as abiraterone or enzalutamide, new cytotoxic anticancer agents such as carbazitaxel, and radioisotope treatment such as radium-223. Recently, studies on the effect of chemotherapy on hormone-naïve metastatic prostate cancer before the development of castration-resistant prostate cancer have been actively published. As a result, various guidelines have recommended docetaxel as the first-line therapy for hormone-naïve metastatic prostate cancer. In this manuscript, we will summarize the basic concepts of androgen deprivation therapy for hormone-naïve metastatic prostate cancer and the main results of research on chemotherapy for hormone-naïve metastatic prostate cancer.
Antineoplastic Agents
;
Castration
;
Drug Therapy*
;
Prostate*
;
Prostatic Neoplasms*
;
Receptors, Androgen
7.The mechanisms of drug resistance in prostate cancer.
Yang HE ; Yang-guang LIU ; Shan CEN ; Jin-ming ZHOU
Acta Pharmaceutica Sinica 2015;50(7):797-801
Drug therapy is one of the efficient methods for prostate cancer treatment. However, drug resistance greatly hindered the treatment of prostate cancer patients. Herein, the mechanisms of drug resistance in prostate cancer have been exhaustively reviewed, and that can provide an alternative strategy and new targets for anti-prostate cancer therapy.
Drug Resistance, Neoplasm
;
Humans
;
Male
;
Prostatic Neoplasms
;
drug therapy
8.Treatment strategies for locally advanced prostate cancer.
Chinese Medical Journal 2014;127(5):957-960
9.Hormonal therapy and chemotherapy for advanced prostate cancer.
Journal of the Korean Medical Association 2015;58(1):30-41
The management of advanced prostate cancer has evolved rapidly. Androgen deprivation therapy, through surgical or medical castration, is the cornerstone of first-line therapy for hormone-naive metastatic prostate cancer. Recently reported results of clinical trials have given answers to questions regarding the best therapeutic agents and strategies, and these have broadened the scope of evidence-based therapy in this field. Although hormone therapy is very effective, the majority of patients eventually develop resistance to hormonal manipulation, leading to so-called castration-resistant prostate cancer. For castration-resistant prostate cancer, docetaxel-based chemotherapy had been the only approved agent to show a survival benefit for several years. However, over the last five years, significant advances in the field have led to the approval of several new agents with different mechanisms of action, such as the new androgen pathway inhibitors abiraterone and enzalutamide, a new cytotoxic agent, cabazitaxel, and new bone-seeking agents such as radium-223, which have all been associated with improved quality of life and pain palliation and an increase in survival. Herein, recent developments in hormone therapy and chemotherapy for advanced prostate cancer are reviewed and some of the trials with important results are summarized. As treatment options have expanded and developed rapidly, the selection of the most appropriate agent and administration method through multidisciplinary management is much more important than simply giving newly approved agents to maximize the clinical outcome for patients with advanced, especially castration-resistant, prostate cancer.
Castration
;
Drug Therapy*
;
Humans
;
Neoplasm Metastasis
;
Prostatic Neoplasms*
;
Quality of Life
10.Radiotherapy for prostate cancer.
Journal of the Korean Medical Association 2015;58(1):21-29
Radiotherapy has an important role in the management of prostate cancer patients. It can be used as definitive treatment in place of surgery, postoperative adjuvant radiotherapy, or salvage treatment when recurrences develop after surgery. During definitive radiotherapy treatment, dose escalation can improve biochemical control but has not led to improved survival to date. Hypofractionated radiotherapy is applied for prostate cancer treatment, since prostate cancer has a low alpha/beta ratio. Contrary to theoretical expectations, hypofractionated treatment does not show improved therapeutic results and decreased toxicity, but it can reduce overall treatment time. Ongoing non-inferiority trials may assist in determining optimal hypofractionated treatment regimens. Adjuvant radiotherapy in patients with pathological T3 or positive resection margins can improve biochemical control and might increase overall survival. However, there is debate regarding the superiority of adjuvant radiotherapy over early salvage radiotherapy in high-risk patients after surgery. To address this issue, it will be necessary to wait for the results of current randomized trials.
Humans
;
Prostatic Neoplasms*
;
Proton Therapy
;
Radiotherapy*
;
Radiotherapy, Adjuvant
;
Recurrence